title: Carboplatin, methotrexate, and vinblastine in patients with bladder cancer who were ineligible for cisplatin-based chemotherapy.
abstract: BACKGROUND
  A Phase II trial with a new regimen of methotrexate, carboplatin, and vinblastine (M-CAVI) was conducted for patients with bladder cancer who could not receive cisplatin-based chemotherapy.
  
  
  METHODS
  Treatment consisted of methotrexate (30 mg/m2) on days 1, 15, and 22; carboplatin (300 mg/m2) on day 2; and vinblastine (3 mg/m2) on days 2, 15, and 22, scheduled at 28-day intervals. The dosage of carboplatin was adjusted for creatinine clearance. Twenty-five patients with metastatic (n = 9) or locally advanced or locoregional bladder cancer with a poor prognosis (n = 16) were treated with M-CAVI. Fifteen patients had abnormal serum creatinine levels, 4 had a low performance status, 3 had cardiac disease, and 3 were older than 70 years old.
  
  
  RESULTS
  Among 23 patients assessable for clinical response, the response rate was 48%. The median duration of response for metastatic disease was 7 months. Among nine patients assessable for pathologic response, there were two complete responses and three partial responses. The toxic effects have been moderate.
  
  
  CONCLUSIONS
  M-CAVI is an active and well-tolerated regimen that can be used in patients with bladder cancer who are ineligible to receive cisplatin-based chemotherapy.
authors.affiliation: Department of Medical Oncology, Hospital Valle Hebron, Barcelona, Spain.
authors.forename: J
authors.initials: J
authors.lastname: Bellmunt
authors.forename: J
authors.initials: J
authors.lastname: Albanell
authors.forename: O S
authors.initials: OS
authors.lastname: Gallego
authors.forename: A
authors.initials: A
authors.lastname: Ribas
authors.forename: P
authors.initials: P
authors.lastname: Vicente
authors.forename: J
authors.initials: J
authors.lastname: Carulla
authors.forename: J
authors.initials: J
authors.lastname: De Torres
authors.forename: J
authors.initials: J
authors.lastname: Morote
authors.forename: M
authors.initials: M
authors.lastname: Lopez
authors.forename: L A
authors.initials: LA
authors.lastname: Solé
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage; D002945:Cisplatin / Q000009:adverse effects; D003131:Combined Modality Therapy; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D016019:Survival Analysis; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000601:surgery; D014747:Vinblastine / Q000008:administration & dosage
chemical_list: D014747:Vinblastine; D016190:Carboplatin; D002945:Cisplatin; D008727:Methotrexate